Project Grant R01DK145695
Award Date 8/17/26
Completion Date 4/30/31
Dollars Obligated $890K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1,677,898 on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop fat and iron-corrected quantitative MRI T1 mapping as a non-invasive biomarker for evaluating chronic liver disease, particularly metabolic-associated steatohepatitis (MASH). The project addresses the clinical need for non-invasive assessment of liver pathology...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $816,825 on April 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how injured podocytes communicate with parietal epithelial cells to drive proliferative glomerulopathy, specifically whether podocyte-derived exosomes mediate this cell-to-cell signaling in rapidly progressive glomerulonephritis. The research uses...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $874,741 on June 1, 2026, to investigate transcriptional mechanisms of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research identifies and characterizes transcription factors that regulate collagen production in hepatic stellate cells, a key driver of liver...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $874,673 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how suppression of 5-aminolevulinic acid synthase 1 (ALAS1) enhances therapeutic RNA interference activity. The project tests a novel genetic strategy to improve the efficacy of small interfering RNAs (siRNAs) in extrahepatic tissues where...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $672,000 on August 14, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a randomized feasibility trial testing isocaloric navy bean substitution as a dietary intervention in adults with metabolic dysfunction-associated steatotic liver disease and advanced fibrosis. The recipient will conduct a single-site, 24-week,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $743,862 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on macrophage mitochondrial metabolism and metabolic dysfunction-associated steatotic liver disease (MASLD). The research investigates how alterations in macrophage composition and function contribute to MASH (metabolic dysfunction-associated...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Albert Einstein College of Medicine $109,652 on September 16, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate chaperone-mediated autophagy failure in metabolic dysfunction-associated steatotic liver disease progression. The research examines how chaperone-mediated autophagy, a selective cellular degradation process, contributes to hepatic metabolic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $850,096 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of S100A9+ macrophages and monocytic myeloid-derived suppressor cells in driving liver fibrosis in metabolic dysfunction-associated steatotic liver disease and steatohepatitis (MASLD/MASH). The research leverages advanced multi-omics...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $155,832 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate matrix metalloproteinase-7 (MMP7)–expressing hepatic stellate cells as drivers of fibrosis progression in biliary atresia. The funded project will define the transcriptomic and spatial identity of MMP7+ hepatic stellate cells in biliary atresia...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Administrators Of Tulane Educational Fund (Tulane University) $651,222 on August 10, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic research on molecular mechanisms driving metabolic dysfunction-associated steatohepatitis (MASH). The research investigates how ROBO1 (Roundabout Receptor 1), regulated by YAP and LHX2, promotes liver fibrosis in...